Skip to main content

Development of sensitive methodologies for exploitation of early epigenetic marker diagnosis in major types of cancer

Ziel

Cancer is one of the major causes of mortality. Epithelial cells become malignant after accumulating genetic mutations followed by morphological changes in the epithelium. DNA Alterations include stable genetic changes in oncogenes, tumor suppressor genes and reversible epigenetic changes. Different forms of epigenetic mechanisms have been shown to modify the expression of key genes during tumour progression. Promoter DNA hypermethylation of tumour suppressor genes or DNA repair genes, and covalent histone modifications appear in early stages of neoplasia. Methods to identify early markers in different types of cancer are being developed, although very few are specific and sensitive enough to be applied in the clinic. The aim of the present proposal is to develop sensitive and specific methodologies to identify early epigenetic markers for major types of cancer, like prostate and colorectal cancer. This project is based on recent findings that selected covalent histone modifications and their modifying enzymes can be early markers of tumourigenesis. For this purpose, the following will be applied. a) selected covalent histone modification like acetylation, methylation, phosphorylation, ubiquitination among others b) their modifying enzymes, like DNA (de)methylases and histone (de)acetylases, (de)methyltransferases c) appropriate diagnostic methods and tests for detection of selected markers in clinical samples. These markers are revealed from studies in cell and animal models as well from patient cohorts. Non-invasive diagnostic methods based on technologies developed in the participating organizations will be tested in clinical samples. Appropriately selected clinical samples will be utilized according to EU and national ethical procedures. The major task of this consortium will be the development of methods to be applied in the clinic for the immediate benefit of cancer patients.

Wissenschaftliches Gebiet

  • /Naturwissenschaften/Biowissenschaften/Genetik und Vererbung/Mutation
  • /Sozialwissenschaften/Soziologie/Demografie/Sterblichkeit
  • /Medizin- und Gesundheitswissenschaften/Klinische Medizin/Onkologie/Krebs/Darmkrebs

Aufforderung zur Vorschlagseinreichung

FP7-HEALTH-2009-single-stage
Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

CP-FP - Small or medium-scale focused research project

Koordinator

ETHNIKO IDRYMA EREVNON
Adresse
Vas Konstantinou 48
11635 Athina
Greece
Aktivitätstyp
Research Organisations
EU-Beitrag
€ 504 584
Kontakt Verwaltung
Alexander Pintzas (Prof.)

Beteiligte (6)

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
EU-Beitrag
€ 331 176
Adresse
Wellington Square University Offices
OX1 2JD Oxford
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Walter Bodmer (Prof.)
INSTITUTO PORTUGUES DE ONCOLOGIA DO PORTO FRANCISCO GENTIL, EPE
Portugal
EU-Beitrag
€ 330 000
Adresse
Rua Antonio Bernardino Almeida
4200-072 Porto
Aktivitätstyp
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Kontakt Verwaltung
Carmen Jeronimo (Prof.)
CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET MEDECINE
Frankreich
EU-Beitrag
€ 401 999
Adresse
Rue Laurent Fries 1
67404 Illkirch Graffenstaden
Aktivitätstyp
Research Organisations
Kontakt Verwaltung
Steve Brooks (Dr.)
BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING
Greece
EU-Beitrag
€ 411 200
Adresse
Fleming Street 34
16672 Vari-athens
Aktivitätstyp
Research Organisations
Kontakt Verwaltung
George Kollias (Dr.)
UNIVERSITAETSKLINIKUM FREIBURG
Deutschland
EU-Beitrag
€ 499 500
Adresse
Hugstetter Strasse 49
79106 Freiburg
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Gerhard Henninger (Mr.)
TARGOS MOLECULAR PATHOLOGY GMBH
Deutschland
EU-Beitrag
€ 365 400
Adresse
Germaniastrasse 7
34119 Kassel
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Thomas Henkel (Dr.)